SKLB1028, a novel oral multikinase inhibitor of EGFR, FLT3 and Abl, displays exceptional activity in models of FLT3-driven AML and considerable potency in models of CML harboring Abl mutants-Reference-Cited by-同舟云学术

SKLB1028, a novel oral multikinase inhibitor of EGFR, FLT3 and Abl, displays exceptional activity in models of FLT3-driven AML and considerable potency in models of CML harboring Abl mutants

Published:2012-03-09 Issue:8 Volume:26 Page:1892-1895
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Cao Z-X,Liu J-J,Zheng R-L,Yang J,Zhong L,Xu Y,Wang L-J,Zhang C-H,Wang B-L,Ma S,Wang Z-R,Xie H-Z,Wei Y-Q,Yang S-Y

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu201267.pdf

Reference15 articles.

1. Jongen-Lavrencic M, Sun SM, Dijkstra MK, Valk PJM, Löwenberg B . MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia. Blood 2008; 11: 5078–5085.

2. Tyner JW, Walters DK, Willis SG, Luttropp M, Oost J, Loraux M et al. RNAi screening of the tyrosine kinome identifies therapeutic targets in acute myeloid leukemia. Blood 2008; 111: 2238–2245.

3. Loriaux MM, Levine RL, Tyner JW, Fröhling S, Scholl C, Stoffregen EP et al. High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia. Blood 2008; 111: 4788–4796.

4. Kantarjian HM, Giles F, Quintás-Cardama AQ, Cortes J . Important therapeutic targets in chronic myelogenous leukemia. Clin Cancer Res 2007; 13: 1089–1097.

5. Gilliland DG, Griffin JD . The roles of FLT3 in hematopoiesis and leukemia. Blood 2002; 100: 1532–1542.

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Harmonizing the craft of crafting clinically endorsed small-molecule BCR-ABL tyrosine kinase inhibitors for the treatment of hematological malignancies;European Journal of Pharmaceutical Sciences;2024-02

2. Addition of venetoclax to myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in high-risk AML;Annals of Medicine;2023-01-11

3. Small molecules in targeted cancer therapy: advances, challenges, and future perspectives;Signal Transduction and Targeted Therapy;2021-05-31

4. Discovery of small molecule FLT3 inhibitors that are able to overcome drug-resistant mutations;Bioorganic & Medicinal Chemistry Letters;2020-11

5. Recent advances in FLT3 inhibitors for acute myeloid leukemia;Future Medicinal Chemistry;2020-05